Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cangrelor Can’t Escape Its Past At FDA Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.

Advertisement

Related Content

Medicines Co. Gains Kengreal Approval; Can It Alter Clinical Practice Too?
Cangrelor Survives Second Advisory Committee, But Narrowly
Cangrelor’s Second Advisory Committee Could Be The Charm
The Medicines Co.’s Slimmer Cangrelor Filing Slated For April Panel Review
Regulatory Briefs: Novartis And GSK See Approvals, TMC And Acorda Don’t
FDA’s Cangrelor “Complete Response” Leaves Room For Approval Without New Trial
TMC Still Optimistic About Cangrelor Approval Despite Negative Opinion
Cangrelor Advisory Cmte. Unsure Whether Plavix Even Needs Replacing
Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No
Can The Medicines Company Rebound From A Phase III Blow?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel